Preparing to Import Medical Devices Before U.S. Commercial Launch
START WITH THE RIGHT REGULATORY PATHWAY
A successful U.S. product launch begins long before the first commercial shipment. This article outlines the regulatory, labeling, and import planning needed to help medical devices clear customs and FDA without unnecessary delays.
Commercial launch planning should begin before the first sales shipment is booked—but “before launch” should not be confused with permission to import unapproved commercial inventory. The first question is the lawful purpose of the shipment. A device intended for commercial distribution generally must already be legally marketable in the United States through a 510(k) clearance, De Novo grant, PMA approval, or applicable exemption. Earlier imports may be possible for a properly documented clinical investigation, testing, evaluation, demonstration, repair, or another recognized noncommercial purpose, but the declared intended use, supporting records, handling controls, and ultimate disposition must match that pathway.
Complete the Regulatory Chain
For a commercial-launch shipment, the regulatory chain should be complete before departure. The foreign manufacturer and any other required establishments should be correctly registered and associated with the device listing; the foreign establishment should have a designated U.S. Agent; the device should be listed under the correct product code and marketing authorization; and the U.S. Initial Importer should be identified and registered. The Importer of Record, Initial Importer, U.S. Agent, consignee, warehouse, distributor, and customs broker may be different organizations, so their responsibilities should be mapped rather than assumed.
Labeling should also be treated as an import prerequisite, not a post-arrival project. The commercial configuration should carry compliant English-language labeling, intended-use statements, prescription or OTC status, manufacturer or distributor identification, applicable UDI information, and any device-specific warnings or instructions. Radiation-emitting products may require additional reports, accession numbers, declarations, or performance-standard documentation. Packaging, model numbers, quantities, and product descriptions should remain consistent across labels, invoices, listings, and broker instructions.
The customs and FDA entry dataset should be validated before the shipment is tendered. This includes the Importer of Record, customs bond, HTS classification, customs value, country of origin, manufacturer and shipper identities, FDA product code, Intended Use Code, Affirmations of Compliance, establishment-registration and listing references, authorization number where applicable, consignee, and accurate invoice descriptions. Even a lawful device can be delayed when the entry data points to the wrong establishment, product code, listing, intended use, or regulatory status.
A useful launch-readiness test is whether the manufacturer, importer, broker, and receiving operation can all describe the same product, transaction, regulatory basis, and disposition without contradiction. Resolving those points before departure reduces detention risk and prevents the first commercial shipment from becoming the test case for an unfinished import process.
MDD Options can coordinate this pre-launch work across FDA registration and listing, U.S. Agent, GUDID and labeling readiness, Importer of Record and Initial Importer roles, broker instructions, and entry-data verification. Where earlier lawful shipments support clinical studies, pilot work, or real-world-evidence activities, MDD Studies can manage the study pathway.